Schrodinger, Inc. Q3 2026 Earnings Recap

Schrödinger’s shares rose 0.9%, a roughly flat reaction. The company raised full-year ACV and drug discovery revenue guidance, while ACV growth excluding contribution ACV was 24%; the call also highlighted ongoing customer evaluations for newer products.

Key Takeaways

• ACV grew 17%, or 24% excluding contribution ACV, driven by adoption in large pharma, new products, biotech and materials customers, and customer additions.
• Management raised full-year guidance for ACV and drug discovery revenue, citing third-quarter performance.
• Bunsen handled approximately 80% of the company’s high-throughput calculations on its internal compute cluster; multiple customers are evaluating it.
• Predictive toxicology evaluations are progressing, and the platform can now assess more than 80 potential off-target proteins computationally.
• Schrödinger received a milestone payment tied to progress in Structured Therapeutics’ oral amylin program; Takeda’s application for zasocitinib was accepted for priority review.